Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience
Aim:The aim of this study was to evaluate the incidence of hypophosphatemia after ferric carboxymaltose (FCM) infusion and the factors affecting hypophosphatemia.Materials and Methods:Ninety-two patients who received FCM treatment for iron deficiency anemia (IDA) were included in the study. Phosphor...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayincilik
2021-08-01
|
| Series: | Namık Kemal Tıp Dergisi |
| Subjects: | |
| Online Access: |
http://namikkemalmedj.com/archives/archive-detail/article-preview/ncidence-of-hypophosphatemia-after-ferric-carboxym/48588
|
| _version_ | 1797906840622727168 |
|---|---|
| author | Esra TERZİ DEMİRSOY |
| author_facet | Esra TERZİ DEMİRSOY |
| author_sort | Esra TERZİ DEMİRSOY |
| collection | DOAJ |
| description | Aim:The aim of this study was to evaluate the incidence of hypophosphatemia after ferric carboxymaltose (FCM) infusion and the factors affecting hypophosphatemia.Materials and Methods:Ninety-two patients who received FCM treatment for iron deficiency anemia (IDA) were included in the study. Phosphorus, calcium, magnesium, 25-hydroxy vitamin D, and parathyroid hormone levels before and after FCM infusion were obtained from the medical records. Hypophosphatemia was defined as serum phosphorus level of <2.5 mg/dL and severe hypophosphatemia as <1 mg/dL. The cut-off value for baseline phosphorus in predicting hypophosphatemia was detected as 3.4 mg/mL with the ROC analysis.Results:Seventy-seven of the patients were women. The mean age was 47.5±15.5 (18-85) years. Thirty of the patients (32.6%) were given 500 mg iron as FCM and 62 patients (67.4%) were given 1000 mg iron as FCM. The level of serum phosphorus measured 10-14 days after FCM was determined lower than the baseline level (2.22±0.57 mg/dL vs 3.34±0.39 mg/dL, p<0.000). Hypophosphatemia was observed in 62 patients (67.4%) after FCM infusion. Severe hypophosphatemia was seen in only 2 patients (2.1%). Patients given a dose of 1000 mg FCM had a higher incidence of hypophosphatemia compared to those given 500 mg FCM (75.8% vs 50%, p=0.013). Baseline phosphorus level of 3.4 mg/dL was associated with an increased risk of developing hypophosphatemia with an odds ratio of 9.2 (p=0.001; 95% confidence interval: 3.41-25.21). On logistic Independentregression analysis, it was found that baseline phosphorus level and a dose of 1000 mg FCM were independent risk factors for the development of hypophosphatemia.Conclusion:The incidence of hypophosphatemia due to FCM in our study was consistent with the literature. When FCM treatment is given to patients with IDA, the patients should be evaluated according to their baseline phosphorus level, the dose of FCM and frequency of administration, and it should be kept in mind to follow the phosphorus level in patients with risk for hypophosphatemia. |
| first_indexed | 2024-04-10T10:26:58Z |
| format | Article |
| id | doaj.art-cd2952c9377949be9b096ce84551f80d |
| institution | Directory Open Access Journal |
| issn | 2587-0262 |
| language | English |
| last_indexed | 2024-04-10T10:26:58Z |
| publishDate | 2021-08-01 |
| publisher | Galenos Yayincilik |
| record_format | Article |
| series | Namık Kemal Tıp Dergisi |
| spelling | doaj.art-cd2952c9377949be9b096ce84551f80d2023-02-15T16:21:22ZengGalenos YayincilikNamık Kemal Tıp Dergisi2587-02622021-08-019220120610.4274/nkmj.galenos.2021.3825813049054Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center ExperienceEsra TERZİ DEMİRSOY0 Sağlık Bilimleri Üniversitesi, Derince Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, Kocaeli, Türkiye Aim:The aim of this study was to evaluate the incidence of hypophosphatemia after ferric carboxymaltose (FCM) infusion and the factors affecting hypophosphatemia.Materials and Methods:Ninety-two patients who received FCM treatment for iron deficiency anemia (IDA) were included in the study. Phosphorus, calcium, magnesium, 25-hydroxy vitamin D, and parathyroid hormone levels before and after FCM infusion were obtained from the medical records. Hypophosphatemia was defined as serum phosphorus level of <2.5 mg/dL and severe hypophosphatemia as <1 mg/dL. The cut-off value for baseline phosphorus in predicting hypophosphatemia was detected as 3.4 mg/mL with the ROC analysis.Results:Seventy-seven of the patients were women. The mean age was 47.5±15.5 (18-85) years. Thirty of the patients (32.6%) were given 500 mg iron as FCM and 62 patients (67.4%) were given 1000 mg iron as FCM. The level of serum phosphorus measured 10-14 days after FCM was determined lower than the baseline level (2.22±0.57 mg/dL vs 3.34±0.39 mg/dL, p<0.000). Hypophosphatemia was observed in 62 patients (67.4%) after FCM infusion. Severe hypophosphatemia was seen in only 2 patients (2.1%). Patients given a dose of 1000 mg FCM had a higher incidence of hypophosphatemia compared to those given 500 mg FCM (75.8% vs 50%, p=0.013). Baseline phosphorus level of 3.4 mg/dL was associated with an increased risk of developing hypophosphatemia with an odds ratio of 9.2 (p=0.001; 95% confidence interval: 3.41-25.21). On logistic Independentregression analysis, it was found that baseline phosphorus level and a dose of 1000 mg FCM were independent risk factors for the development of hypophosphatemia.Conclusion:The incidence of hypophosphatemia due to FCM in our study was consistent with the literature. When FCM treatment is given to patients with IDA, the patients should be evaluated according to their baseline phosphorus level, the dose of FCM and frequency of administration, and it should be kept in mind to follow the phosphorus level in patients with risk for hypophosphatemia. http://namikkemalmedj.com/archives/archive-detail/article-preview/ncidence-of-hypophosphatemia-after-ferric-carboxym/48588 ferric carboxymaltoseiron deficiency anemiahypophosphatemia |
| spellingShingle | Esra TERZİ DEMİRSOY Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience Namık Kemal Tıp Dergisi ferric carboxymaltose iron deficiency anemia hypophosphatemia |
| title | Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience |
| title_full | Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience |
| title_fullStr | Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience |
| title_full_unstemmed | Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience |
| title_short | Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience |
| title_sort | incidence of hypophosphatemia after ferric carboxymaltose treatment single center experience |
| topic | ferric carboxymaltose iron deficiency anemia hypophosphatemia |
| url |
http://namikkemalmedj.com/archives/archive-detail/article-preview/ncidence-of-hypophosphatemia-after-ferric-carboxym/48588
|
| work_keys_str_mv | AT esraterzidemirsoy incidenceofhypophosphatemiaafterferriccarboxymaltosetreatmentsinglecenterexperience |